The Latest Cardiac and Vascular News
Dr. Felker and Dr. Udelson join current advisors to support the development of alfapump® DSR for the management of fluid overload in patients with heart failure GHENT, Belgium, Oct. 15, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites […]
Published: Sep 03, 2020 POSEIDON – Implants in Canada continue; interim results expected H1 2021 RED DESERT – Implants continue; interim results expected Q4 2020 DSR (Direct Sodium Removal) – Fundamental patents allowed in U.S. and Europe Continued growth in […]
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 28 July 2020, 07:00 CEST Cash runway extended into H2 2021 enabling Sequana Medical to reach key near term value inflection points POSEIDON – implants resumed and interim results expected in Q1 2021 (North […]
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW PRESS RELEASE 25 JUNE 2020 07:00 […]
Continued strong progress in U.S. NASH-related and global heart failure programs Successfully raised €19 million in Q1 2020 extending cash runway into H1 2021 Conference call with live webcast presentation today at 14:00 CET / 09:00 ET GHENT, Belgium, March 19, 2020 […]
Positive pre-clinical and clinical proof-of-concept data of Sequana Medical’s innovative DSR therapy published in top tier peer-reviewed cardiovascular journal Data demonstrates potential for treatment of volume overload due to heart failure Ghent, BELGIUM – 10 January 2020 – Sequana Medical NV […]
Dr. Butler, Dr. Costanzo, Dr. Tang and Dr. Testani to advise on alfapump® DSR development GHENT, Belgium, Sept. 19, 2019 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), innovators in the management of fluid overload in […]
